- Q3 2026 revenue $500,000 (-99% YoY), missing estimates for the quarter
- Ended Q3 with $558.9M in cash, expected to fund operations into 2H 2028
- Dosed first patient in Phase 1/2 trial of HPK1 degrader ARV-6723
Tuesday, November 3, 2026
Arvinas delays LRRK2 degrader ARV-102, plans EU/UK Phase 1b start in 2027 as U.S. hold persists
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.